Resapp Health Osake

Resapp Health P/B

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Resapp Health (RAP.AX) 23.6.2026 päivämäärällä on 47,18.Edellisenä vuonna P/B (Hinta-kirjanpitoarvo-suhde) oli 4,28 — muutos 1 002,67 % (korkeampi).

P/B

47,18

YoY

1 002,67%

Viimeksi päivitetty:

P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Resapp Health on 2026 47,18 . P/B (Hinta-kirjanpitoarvo-suhde) yhtiöstä Resapp Health oli 2025 4,28 . Se laskee 1 002,67% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Resapp Health Osakeanalyysi

Mitä Resapp Health tekee? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Resapp Health osakkeesta

P/B (Hinta-kirjanpitoarvo-suhde) oli Resapp Health 4,28 47,18

Access this data via the Eulerpool API

Arvostus — Resapp Health

Kaikki tunnusluvut — Resapp Health